Igor Fisch, PhDRajesh Lohakare
Igor cofounded Selexis in 2001 and he served as chief executive officer from 2001 to 2020.
Igor is passionate and dedicated to scientific excellence. In just 15 years, Igor has been instrumental in building Selexis into a world-class leader in cell line development and biologic drug discovery. Cell lines that have been developed with Selexis’ technology are being used from discovery to late-phase clinical trials. With a small investment of 810,000 CHF (prize money and angel funds), Igor has guided the company through tremendous growth, passing its breakeven point in 2005 into a profitable life science company.
Igor is an accomplished protein chemist and molecular biologist. Prior to Selexis, he was an assistant professor in the Chemical Engineering Department of the Polytechnical School in Lausanne (EPFL). He obtained his PhD under Professor Robin Offord at the University of Geneva and pursued his postdoctoral studies in the laboratory of Prof. Sir Gregory Winter at the Medical Research Council (MRC) in Cambridge, UK. In parallel with his research and teaching activities, Igor obtained several awards, including the De Vigier Prize and the NETS Best Prize.
Igor co-founded BioXpress SA, a provider of high-quality biosimilars, and sits on its advisory board. He is on the board of the Venture Kick initiative, which provides support and funding to translate promising business ideas from Swiss Universities into start-up companies. Igor previously was a board member of Viroblock SA, a company that he helped create, which is developing a unique range of proprietary anti-viral products. He was previously a member of the board of directors of Affitech A/S, a biopharmaceutical company listed on NASDAQ OMX Copenhagen, dedicated to the discovery and development of human antibody-based therapeutics.
In 2016, BioProcess International named Igor as the winner of the 2016 “Excellence in Leadership Award.” This honor was bestowed to Igor as an outstanding leader who defines excellence and who has enabled more effective, less expensive biotherapeutic development and manufacturing.